Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
95,714,968
-
Total 13F shares
-
72,231,974
-
Share change
-
-93,633
-
Total reported value
-
$4,681,193,470
-
Put/Call ratio
-
90%
-
Price per share
-
$64.81
-
Number of holders
-
433
-
Value change
-
+$29,481,399
-
Number of buys
-
216
-
Number of sells
-
175
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q3 2025
As of 30 Sep 2025,
CRISPR Therapeutics AG - Common Stock (CRSP) was held by
433 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
72,231,974 shares.
The largest 10 holders included
ARK Investment Management LLC, BlackRock, Inc., Capital International Investors, Orbis Allan Gray Ltd, STATE STREET CORP, T. Rowe Price Investment Management, Inc., VANGUARD GROUP INC, UBS Group AG, Amova Asset Management Americas, Inc., and Sumitomo Mitsui Trust Group, Inc..
This page lists
434
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.